Aliases & Classifications for Pulmonary Tuberculosis

MalaCards integrated aliases for Pulmonary Tuberculosis:

Name: Pulmonary Tuberculosis 12 14
Tuberculosis, Pulmonary 72 41 69
Tuberculosis Pulmonary 51
Ptb 44

Classifications:



External Ids:

Disease Ontology 12 DOID:2957
ICD10 32 A15 A15.0
ICD9CM 34 011 011.9 011.90
MeSH 41 D014397
NCIt 46 C26899
UMLS 69 C0041327

Summaries for Pulmonary Tuberculosis

Disease Ontology : 12 A tuberculosis that is a contagious disease located in lungs. The infection has symptom fever, has symptom cough, has symptom difficulty in breathing, has symptom inflammatory infiltrations, has symptom formation of tubercles, has symptom caseation, has symptom pleural effusion, and has symptom fibrosis.

MalaCards based summary : Pulmonary Tuberculosis, also known as tuberculosis, pulmonary, is related to pneumonia and panuveitis, and has symptoms including fever, cough and difficulty in breathing. An important gene associated with Pulmonary Tuberculosis is MBL2 (Mannose Binding Lectin 2), and among its related pathways/superpathways are Innate Immune System and TGF-Beta Pathway. The drugs Priftin and Estradiol have been mentioned in the context of this disorder. Affiliated tissues include lungs, lung and testes, and related phenotypes are hematopoietic system and homeostasis/metabolism

Wikipedia : 72 Tuberculosis (TB) is an infectious disease usually caused by the bacterium Mycobacterium tuberculosis... more...

Related Diseases for Pulmonary Tuberculosis

Diseases related to Pulmonary Tuberculosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 392)
# Related Disease Score Top Affiliating Genes
1 pneumonia 30.4 IL10 MBL2 TLR2 TLR9 TNF
2 panuveitis 30.3 HLA-DRB1 IL10 TNF
3 nontuberculous mycobacterial lung disease 30.2 HLA-DRB1 SLC11A1 TLR2 TNF
4 oral tuberculosis 30.2 IL2 TNF
5 pleurisy 30.1 ADA IFNG IL2 TNF
6 tuberculous peritonitis 30.1 ADA IFNG TNF
7 aspergillosis 30.1 IFNG IL10 IL4 MBL2 TLR2 TLR9
8 bronchial disease 30.1 IL10 IL4 TLR9 TNF
9 pulmonary sarcoidosis 30.0 IFNG IL18 IL2 TNF
10 arthritis 30.0 HLA-DRB1 IFNG IL10 IL18 TNF
11 bronchiolitis obliterans 30.0 IFNG IL10 TNF
12 cryptococcosis 30.0 IFNG IL4 MBL2 TLR9
13 herpes zoster 30.0 IFNG IL10 IL2
14 neuritis 29.9 IFNG IL4 TNF
15 endocarditis 29.9 IL10 TLR2 TNF
16 ige responsiveness, atopic 29.9 IFNG IL10 IL4
17 chronic inflammatory demyelinating polyneuropathy 29.9 HLA-DRB1 HP
18 melioidosis 29.8 IFNG IL10 IL18 TLR2 TNF
19 interstitial lung disease 29.8 IFNG IL10 IL4 TNF
20 leprosy 3 29.8 IFNG IL10 IL2 IL4 SLC11A1 TLR2
21 aplastic anemia 29.8 HLA-DRB1 IFNG IL2 IL4 TNF
22 multidrug-resistant tuberculosis 29.8 IL10 INHA SLC11A1 TNF VDR
23 peritonitis 29.7 ADA IFNG IL10 TLR2 TNF
24 allergic rhinitis 29.7 IFNG IL10 IL18 IL4
25 pleural tuberculosis 29.6 ADA IFNG IL18 TNF
26 toxoplasmosis 29.6 IFNG IL10 IL4 TLR9 TNF
27 human immunodeficiency virus type 1 29.5 ADA IFNG IL10 IL2 TNF
28 bronchiolitis 29.5 IFNG IL10 IL4 TLR9 TNF
29 paracoccidioidomycosis 29.5 IFNG IL10 IL18 IL2 IL4 TLR2
30 chronic granulomatous disease 29.4 IFNG TLR9 TNF
31 schistosomiasis 29.3 IFNG IFNGR1 IL10 IL2 IL4 TNF
32 meningitis 29.3 ADA IFNG IL10 MBL2 TLR2 TLR9
33 extrapulmonary tuberculosis 29.3 ADA IFNG IL10 P2RX7 SLC11A1 TLR2
34 crohn's disease 29.2 HP IFNG IL10 SLC11A1 TLR9 TNF
35 tuberculous meningitis 29.2 ADA NAT2 TLR2 TNF
36 lepromatous leprosy 29.1 IFNG IFNGR1 IL10 IL12RB1 IL2 TLR2
37 cutaneous leishmaniasis 29.1 IFNG IL10 IL4 SLC11A1 TLR2 TLR9
38 lymphadenitis 29.0 IFNG IFNGR1 IL10 IL12RB1 IL18 SLC11A1
39 rheumatoid arthritis 29.0 HLA-DRB1 IFNG IL10 IL18 IL2 IL4
40 asthma 29.0 HLA-DRB1 IFNG IL10 IL18 IL4 TLR9
41 leishmaniasis 28.7 HLA-DRB1 IFNG IFNGR1 IL10 IL4 SLC11A1
42 systemic lupus erythematosus 28.5 HLA-DRB1 IFNG IL10 IL18 IL2 IL4
43 mycobacterium tuberculosis 1 27.7 ADA IFNG IFNGR1 IL10 IL12RB1 IL18
44 laryngeal tuberculosis 11.2
45 nosophobia 10.9
46 punctate inner choroidopathy 10.6 IL10 TNF
47 mycoplasmal pneumonia 10.6 IFNG IL4
48 juvenile myasthenia gravis 10.6 HLA-DRB1 IL10
49 chronic beryllium disease 10.6 HLA-DRB1 IFNG TNF
50 microscopic polyangiitis 10.5 HLA-DRB1 IL10 TNF

Comorbidity relations with Pulmonary Tuberculosis via Phenotypic Disease Network (PDN):


Acute Cystitis Bronchiectasis
Bronchitis Deficiency Anemia
Heart Disease Iron Deficiency Anemia
Pleural Tuberculosis Postinflammatory Pulmonary Fibrosis
Protein-Energy Malnutrition Respiratory Failure

Graphical network of the top 20 diseases related to Pulmonary Tuberculosis:



Diseases related to Pulmonary Tuberculosis

Symptoms & Phenotypes for Pulmonary Tuberculosis

Symptoms:

12
  • fever
  • cough
  • difficulty in breathing
  • inflammatory infiltrations
  • formation of tubercles
  • caseation
  • pleural effusion
  • fibrosis

UMLS symptoms related to Pulmonary Tuberculosis:


hemoptysis

MGI Mouse Phenotypes related to Pulmonary Tuberculosis:

43 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.41 IL2 IL4 IL12RB1 IL18 INHA IFNG
2 homeostasis/metabolism MP:0005376 10.39 IL10 IL2 IL12RB1 IL4 IL18 IFNG
3 immune system MP:0005387 10.36 INHA IL2 IL4 IL12RB1 IL18 IFNG
4 cellular MP:0005384 10.35 IL10 IL2 IL4 IL18 HP IFNG
5 digestive/alimentary MP:0005381 10.34 INHA IL2 IL4 IL18 IFNG IL10
6 cardiovascular system MP:0005385 10.33 IL10 IL2 IL18 IFNG ADA IFNGR1
7 behavior/neurological MP:0005386 10.3 IL18 IL2 IL10 IL12RB1 IFNGR1 IFNG
8 growth/size/body region MP:0005378 10.27 IL18 IL2 IL10 IL12RB1 IL4 IFNG
9 endocrine/exocrine gland MP:0005379 10.21 IL10 IL2 IL4 IFNGR1 IFNG ADA
10 mortality/aging MP:0010768 10.17 IL10 IL2 IL4 IL18 HP IFNG
11 liver/biliary system MP:0005370 10.07 IL10 IL2 IL4 IFNG ADA IFNGR1
12 integument MP:0010771 10.06 IL10 IL4 IL18 IFNGR1 IFNG TLR2
13 neoplasm MP:0002006 9.91 IL10 IL2 IFNG IFNGR1 HP SLC11A1
14 renal/urinary system MP:0005367 9.81 IL4 HP IFNG ADA IFNGR1 TLR9
15 reproductive system MP:0005389 9.65 IL10 IL2 IL4 IFNGR1 IFNG ADA
16 skeleton MP:0005390 9.32 IL10 IL4 IFNGR1 IFNG ADA P2RX7

Drugs & Therapeutics for Pulmonary Tuberculosis

FDA approved drugs:

# Drug Name Active Ingredient(s) 17 Company Approval Date
1
Priftin 17 RIFAPENTINE Hoechst Marion Roussel June 1998

Drugs for Pulmonary Tuberculosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 257)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-28-2 5757
2
Rifampin Approved Phase 4,Phase 2,Phase 3,Phase 1 13292-46-1 5381226 5458213
3
Calcium Carbonate Approved, Investigational Phase 4,Phase 3 471-34-1
4
Isoniazid Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 54-85-3 3767
5
Pyrazinamide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 98-96-4 1046
6
Norgestimate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 35189-28-7 6540478
7
Moxifloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 151096-09-2, 354812-41-2 152946
8
Rifabutin Approved, Investigational Phase 4,Phase 2 72559-06-9 6323490
9
Streptomycin Approved, Vet_approved Phase 4,Phase 2,Phase 1 57-92-1 19649
10
Ethambutol Approved Phase 4,Phase 2,Phase 3,Phase 1 74-55-5 14052 3279
11
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 2,Phase 1 57-63-6 5991
12
Ofloxacin Approved Phase 4,Phase 3,Phase 2,Phase 1 82419-36-1 4583
13
Levofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 100986-85-4 149096
14
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 1406-16-2
15
Cholecalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2 67-97-0 10883523 5280795 6221
16
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2 50-14-6 5280793
17 Estradiol valerate Phase 4,Phase 3,Phase 2,Phase 1 979-32-8
18 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1
19 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
20 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1
21 Contraceptive Agents Phase 4,Phase 3,Phase 2,Phase 1
22 Contraceptives, Oral Phase 4,Phase 3,Phase 2,Phase 1
23 Contraceptives, Oral, Combined Phase 4,Phase 3,Phase 2,Phase 1
24 Cytochrome P-450 CYP3A Inducers Phase 4,Phase 3,Phase 2,Phase 1
25 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
26 Norgestimate, ethinyl estradiol drug combination Phase 4,Phase 3,Phase 2,Phase 1
27 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
28 Vitamins Phase 4,Phase 3,Phase 2,Phase 1
29 Anti-Bacterial Agents Phase 4,Phase 2,Phase 3,Phase 1
30 Ergocalciferols Phase 4,Phase 3,Phase 2
31 Estradiol 17 beta-cypionate Phase 4,Phase 3,Phase 2,Phase 1
32 Estradiol 3-benzoate Phase 4,Phase 3,Phase 2,Phase 1
33 Hypolipidemic Agents Phase 4,Phase 2,Phase 3,Phase 1
34 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1
35 Polyestradiol phosphate Phase 4,Phase 3,Phase 2,Phase 1
36 Antimetabolites Phase 4,Phase 2,Phase 3,Phase 1
37 Lipid Regulating Agents Phase 4,Phase 2,Phase 3,Phase 1
38 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
39 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2
40 Antitubercular Agents Phase 4,Phase 2,Phase 3,Phase 1
41 Calcium, Dietary Phase 4,Phase 3
42 Renal Agents Phase 4,Phase 3,Phase 1,Phase 2
43 Cytochrome P-450 CYP1A2 Inhibitors Phase 4,Phase 3,Phase 1,Phase 2
44 Vitamin D2 Nutraceutical Phase 4,Phase 3,Phase 2
45 Calciferol Nutraceutical Phase 4,Phase 3,Phase 2
46 Whey Protein Nutraceutical Phase 4
47
Zinc Approved, Investigational Phase 3 7440-66-6 32051 23994
48
Linezolid Approved, Investigational Phase 3,Phase 2,Phase 1 165800-03-3 441401
49
Gatifloxacin Approved, Investigational Phase 3,Phase 1,Phase 2 112811-59-3 5379
50 Zinc sulfate Approved, Investigational Phase 3 7733-02-0

Interventional clinical trials:

(show top 50) (show all 240)

# Name Status NCT ID Phase Drugs
1 Research on New Regimens for Retreatment Pulmonary Tuberculosis Unknown status NCT02331823 Phase 4 Isoniazid Aminosalicylate Tablets;Streptomycin injectable
2 Effect of Supplementary Vitamin D in Patients With Diabetes Mellitus and Pulmonary Tuberculosis Unknown status NCT02169570 Phase 4
3 Multicenter Trial for the Evaluation of a Fixed Dose Combined Tablet for the Treatment of Pulmonary Tuberculosis Unknown status NCT00216333 Phase 4 combined fixed dose combination
4 Effect of Vitamin D as Adjunctive Therapy in Patients With Pulmonary Evolution Tuberculosis Unknown status NCT02464683 Phase 4
5 Simple Verbal Intervention for Adequately Collecting Sputum Unknown status NCT01135043 Phase 4
6 Reintroduction Regimens After Hepatitis During Anti-tuberculosis Treatment Unknown status NCT01395654 Phase 4 isoniazid, rifampin, pyrazinamide
7 Xpert MTB/Rif, a New Tool for the Diagnosis of Pulmonary Tuberculosis in Two Municipalities in Brazil Completed NCT01363765 Phase 4
8 Randomized Trial for Pharmacogenomics-based Tuberculosis Therapy (RT-PGTT) Completed NCT00298870 Phase 4 Isoniazid;isoniazed
9 Improving Community Based Tuberculosis Care in Ethiopia Completed NCT00803322 Phase 4
10 MDR TB, Levofloxacin, Multi-Drug-Resistant Pulmonary Tuberculosis Completed NCT00495339 Phase 4 Levofloxacin
11 The Effectiveness of Health Facility-based and Community-based Care for Tuberculosis Completed NCT00939419 Phase 4
12 Shortened Regimens for Drug-susceptible Pulmonary Tuberculosis Recruiting NCT02901288 Phase 4 Isoniazid;Rifampicin;Pyrazinamide;Ethambutol;Levofloxacin
13 Prevention of Tuberculosis in Prisons Recruiting NCT03028129 Phase 4 Isoniazid 900 milligrams;Placebo
14 Treating Tuberculosis Wasting With a High-protein Supplement Recruiting NCT03302949 Phase 4
15 Rapid Detection of Rifampin and Isoniazid Resistance by PCR Before Tuberculosis (TB) Treatment Initiation Active, not recruiting NCT02231229 Phase 4 conventional therapy
16 Efficacy of HUEXC030 in Subjects With Pulmonary Tuberculosis Unknown status NCT02467608 Phase 2, Phase 3 Isoniazid with HUEXC030 and RZE;HRZE
17 Latency in Pulmonary Tuberculosis Unknown status NCT01154959 Phase 3 Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol
18 Efficacy of Oral Zinc Administration as an Adjunct Therapy in New Pulmonary Tuberculosis (Category I) Patients Unknown status NCT00698386 Phase 3
19 Pulmonary Tuberculosis and Vitamin D Unknown status NCT00507000 Phase 3 Cholecalciferol;Lactose granules
20 A Controlled Trial of a 4-Month Quinolone-Containing Regimen for the Treatment of Pulmonary Tuberculosis Unknown status NCT00216385 Phase 3 Gatifloxacin combined regimen
21 Development of Tuberculosis Diagnostic Kit Unknown status NCT00311207 Phase 3
22 Comparing Two Preventive Regimens for Latent Tuberculosis Infection (LTBI) Unknown status NCT01398618 Phase 3 4-month rifampin vs. 9-month isoniazid
23 L-arginine and Vitamin D Adjunctive Therapy in Pulmonary Tuberculosis (TB) Completed NCT00677339 Phase 3 L-arginine;Vitamin D;Placebo L-arginine;Placebo Vitamin D
24 Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary Tuberculosis Completed NCT00864383 Phase 3 Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin
25 Efficacy and Safety of Immunomodulator as an Adjunct Therapy in New Pulmonary Tuberculosis(Category I) Patients. Completed NCT00341328 Phase 3
26 Efficacy and Safety Study of Immunomodulator as an Adjunct Therapy in Pulmonary Tuberculosis (TB) Retreatment Patients Completed NCT00265226 Phase 3
27 Micronutrient Supplementation in in Paediatric Pulmonary Tuberculosis Completed NCT00801606 Phase 3 Zinc;Micronutrient without zinc;Micronutrient with zinc;Placebo
28 A Clinical Trial to Study the Effect of the Addition of Vitamin D to Conventional Treatment in New Pulmonary Tuberculosis Patients Completed NCT00366470 Phase 3 A. 100,000 IU Cholecalciferol per dose of 3.3ml
29 Nutrition, Diabetes and Pulmonary TB/HIV Completed NCT00311298 Phase 3
30 TBTC Study 22: Efficacy of Once-Weekly Rifapentine and Isoniazid in Treatment of Tuberculosis Completed NCT00023335 Phase 3 Rifapentine;Isoniazid
31 Intensive Smoking-cessation Intervention Versus Smoking-cessation Advice in Smear-positive Patients With Pulmonary Tuberculosis Completed NCT01517022 Phase 3 nicotine replacement therapy
32 Tuberculosis Treatment Shortening Trial Completed NCT00130247 Phase 3 Pyrazinamide;Rifampin;Isoniazid;Ethambutol
33 Vitamin A Therapy for Tuberculosis Completed NCT00057434 Phase 3 multivitamin
34 Adjunct Immunotherapy With Immunoxel in Patients With TB and TB/HIV Completed NCT01061593 Phase 3
35 Trial of Adjunctive Vitamin D in Tuberculosis Treatment Completed NCT00419068 Phase 3 Cholecalciferol;Migliol Placebo Oil
36 The Treatment of Tuberculosis in HIV-Infected Patients Completed NCT00001033 Phase 3 Ethambutol hydrochloride;Isoniazid;Pyrazinamide;Pyridoxine hydrochloride;Levofloxacin;Rifampin
37 High-Dose Isoniazid Adjuvant Therapy for Multidrug Resistant Tuberculosis Completed NCT00513396 Phase 2, Phase 3 Isoniazid;Placebo
38 Treatment Duration for Abdominal Tuberculosis Completed NCT01124929 Phase 3 RNTCP Category I treatment for 6 months;RNTCP Category I treatment for 9months
39 A Study to Compare Three Existing Starting Points of Anti-Retroviral Therapy (ART) Initiation in HIV/Tuberculosis (TB) Co-infected Patients Completed NCT00398996 Phase 3 Early versus intermediate versus late initiation of ART
40 Optimization of the TB Treatment Regimen Cascade Completed NCT02153528 Phase 3 double rimfampicin;Standard TB treatment
41 A Randomised Trial to Evaluate Toxicity and Efficacy of 1200mg and 1800mg Rifampicin for Pulmonary Tuberculosis Recruiting NCT02581527 Phase 3 Rifampicin 1200mg;Rifampicin 1800mg;4FDC
42 TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens Recruiting NCT02410772 Phase 3 rifapentine;rifapentine and moxifloxacin;control
43 Study to Check the Efficacy and Safety of Recombinant BCG Vaccine in Prevention of TB Recurrence in India Recruiting NCT03152903 Phase 2, Phase 3
44 FS-1 Drug for Treatment of Multiple Drug-resistant Tuberculosis Recruiting NCT02607449 Phase 3 FS-1;Placebo
45 Comparison of Local Made and Imported Porous Polyethylene Orbital Implant for Enucleation in Thailand Recruiting NCT01312545 Phase 3
46 Safety and Efficacy of Various Doses and Treatment Durations of Linezolid Plus Bedaquiline and Pretomanid in Participants With Pulmonary TB, XDR-TB, Pre- XDR-TB or Non-responsive/Intolerant MDR-TB (ZeNix) Recruiting NCT03086486 Phase 3 Pretomanid;Linezolid;Bedaquiline;Placebo Linezolid
47 Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis Recruiting NCT02563327 Phase 3 Rifapentine;Moxifloxacin;Rifampin;Isoniazid;Pyrazinamide;Ethambutol
48 The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB Recruiting NCT02409290 Phase 3 Regimen A locally-used WHO-approved MDR-TB regimen;Moxifloxacin;Clofazimine;Ethambutol;Pyrazinamide;Isoniazid;Prothionamide;Kanamycin;Levofloxacin;Bedaquiline
49 Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s) Recruiting NCT02589782 Phase 2, Phase 3 Bedaquiline;Pretomanid;Moxifloxacin;Linezolid;Clofazimine;Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB.
50 Comparing Daily vs Intermittent Regimen of ATT in HIV With Pulmonary Tuberculosis Active, not recruiting NCT00933790 Phase 3 ATT (Ethambutol, Pyrazinamide, INH, Rifampicin)

Search NIH Clinical Center for Pulmonary Tuberculosis

Cochrane evidence based reviews: tuberculosis, pulmonary

Genetic Tests for Pulmonary Tuberculosis

Anatomical Context for Pulmonary Tuberculosis

The Foundational Model of Anatomy Ontology organs/tissues related to Pulmonary Tuberculosis:

18
Lungs

MalaCards organs/tissues related to Pulmonary Tuberculosis:

38
Lung, Testes, T Cells, Monocytes, Whole Blood, Liver, Neutrophil

Publications for Pulmonary Tuberculosis

Articles related to Pulmonary Tuberculosis:

(show top 50) (show all 1331)
# Title Authors Year
1
IgA and IgG against Mycobacterium tuberculosis Rv2031 discriminate between pulmonary tuberculosis patients, Mycobacterium tuberculosis-infected and non-infected individuals. ( 29373577 )
2018
2
The correlation between CT features and glycosylated hemoglobin level in patients with T2DM complicated with primary pulmonary tuberculosis. ( 29430189 )
2018
3
Diagnostic pathways and direct medical costs incurred by new adult pulmonary tuberculosis patients prior to anti-tuberculosis treatment - Tamil Nadu, India. ( 29414980 )
2018
4
Ex vivo expansion of alveolar macrophages with Mycobacterium tuberculosis from the resected lungs of patients with pulmonary tuberculosis. ( 29401466 )
2018
5
Predictors of therapy failure in newly diagnosed pulmonary tuberculosis cases in Beira, Mozambique. ( 29402317 )
2018
6
Africa-wide evaluation of host biomarkers in QuantiFERON supernatants for the diagnosis of pulmonary tuberculosis. ( 29422548 )
2018
7
Molecular epidemiology and drug sensitivity pattern of Mycobacterium tuberculosis strains isolated from pulmonary tuberculosis patients in and around Ambo Town, Central Ethiopia. ( 29447273 )
2018
8
Development of pulmonary tuberculosis following treatment with anti-PD-1 for non-small cell lung cancer. ( 29384034 )
2018
9
Large-scale genomic analysis shows association between homoplastic genetic variation in Mycobacterium tuberculosis genes and meningeal or pulmonary tuberculosis. ( 29402222 )
2018
10
Nutrition Status Among HIV-Positive and HIV-Negative Inpatients with Pulmonary Tuberculosis. ( 29397039 )
2018
11
Management challenge: Optic disc granuloma in pulmonary tuberculosis. ( 29380785 )
2018
12
Emphysema and bronchiectasis in COPD patients with previous pulmonary tuberculosis: computed tomography features and clinical implications. ( 29416328 )
2018
13
Performance of computed tomography versus chest radiography in patients with pulmonary tuberculosis with and without diabetes at a tertiary hospital in Riyadh, Saudi Arabia. ( 29379307 )
2018
14
Activation and Regulation of Blood VI'2 T Cells Are Amplified by TREM-1<sup>+</sup>during Active Pulmonary Tuberculosis. ( 29427420 )
2018
15
T Cell Profile was Altered in Pulmonary Tuberculosis Patients with Type 2 Diabetes. ( 29385117 )
2018
16
Association of TNF-I+, IL-10 and IL-6 promoter polymorphisms in pulmonary tuberculosis patients and their household contacts of younger age group. ( 29406278 )
2018
17
Addison's Disease Caused by Tuberculosis with Atypical Hyperpigmentation and Active Pulmonary Tuberculosis. ( 28717080 )
2017
18
Evaluation of the relationship between MARCO and CD36 single-nucleotide polymorphisms and susceptibility to pulmonary tuberculosis in a Chinese Han population. ( 28693442 )
2017
19
Cold Agglutinin Disease in a Patient of Pulmonary Tuberculosis. ( 28969736 )
2017
20
Trace elements in blood samples of smoker and nonsmoker active pulmonary tuberculosis patients from Jamshoro, Pakistan. ( 28948455 )
2017
21
Utility of Macrophage-activated Marker CD163 for Diagnosis and Prognosis in Pulmonary Tuberculosis. ( 27684274 )
2017
22
Profiling dendritic cell subsets in the patients with active pulmonary tuberculosis. ( 28889065 )
2017
23
Effect of a brief smoking cessation intervention on adult tobacco smokers with pulmonary tuberculosis: A cluster randomized controlled trial from North India. ( 28928319 )
2017
24
Impaired toll like receptor 9 response in pulmonary tuberculosis. ( 27768958 )
2017
25
Stool culture for the diagnosis of pulmonary tuberculosis in children. ( 28904186 )
2017
26
IL-6 and IL-18 cytokine gene variants of pulmonary tuberculosis patients with co-morbid diabetes mellitus and their household contacts in Hyderabad. ( 28652186 )
2017
27
The incidence of subclinical forms of urogenital tuberculosis in patients with pulmonary tuberculosis. ( 28757299 )
2017
28
Risk prediction of pulmonary tuberculosis using genetic and conventional risk factors in adult Korean population. ( 28355295 )
2017
29
Comprehensive understanding of health-seeking behaviour among pulmonary tuberculosis patients in China. ( 28911351 )
2017
30
Drug resistance patterns among extra-pulmonary tuberculosis cases in a tertiary care centre in North India. ( 28911354 )
2017
31
Down-Regulation of Serum High-Mobility Group Box 1 Protein in Patients with Pulmonary Tuberculosis and Nontuberculous Mycobacterial Lung Disease. ( 28416955 )
2017
32
Optic perineuritis simultaneously associated with active pulmonary tuberculosis without intraocular tuberculosis. ( 28944211 )
2017
33
Unbiased Identification of Blood-based Biomarkers for Pulmonary Tuberculosis by Modeling and Mining Molecular Interaction Networks. ( 28065665 )
2017
34
Sonographic Findings of Abdominal Tuberculosis in Children with Pulmonary Tuberculosis. ( 28333710 )
2017
35
IL-10 -1082 A>G (rs1800896) Polymorphism Confers Susceptibility to Pulmonary Tuberculosis in Caucasians But not in Asians and Africans: A Meta-Analysis. ( 28951522 )
2017
36
A comparison of 18F-FDG PET/MR with PET/CT in pulmonary tuberculosis. ( 28885539 )
2017
37
Pulmonary tuberculosis presenting as post-operative fever of unknown origin. ( 28062417 )
2017
38
Prevalence and determinants of delay in diagnosis of pulmonary tuberculosis in Darjeeling district of West Bengal. ( 29417021 )
2017
39
Serum amyloid A, protein Z, and C4b-binding protein I^ chain as new potential biomarkers for pulmonary tuberculosis. ( 28278182 )
2017
40
Evaluation of Xpert MTB/RIF testing for rapid diagnosis of childhood pulmonary tuberculosis in children by Xpert MTB/RIF testing of stool samples in a low resource setting. ( 28886729 )
2017
41
Evaluation of the TB-LAMP assay for the rapid diagnosis of pulmonary tuberculosis in Northern India. ( 28911360 )
2017
42
Cardiovocal Syndrome: A rare cause of hoarseness in a patient with a history of pulmonary tuberculosis. ( 29372095 )
2017
43
S100A12: Friend or foe in pulmonary tuberculosis? ( 28110121 )
2017
44
CT findings of pulmonary tuberculosis and tuberculous pleurisy in diabetes mellitus patients. ( 28185999 )
2017
45
Molecular clustering of patients with diabetes and pulmonary tuberculosis: A systematic review and meta-analysis. ( 28902922 )
2017
46
Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis. ( 28947041 )
2017
47
Population-Based Case-Control Study Assessing the Association between Statins Use and Pulmonary Tuberculosis in Taiwan. ( 28912719 )
2017
48
Pulmonary tuberculosis diagnostic practices among people living with the human immunodeficiency virus in Lesotho. ( 28911357 )
2017
49
Diagnostic delay and associated factors among patients with pulmonary tuberculosis in Kerala. ( 29417023 )
2017
50
Pulmonary Tuberculosis: Role of Radiology in Diagnosis and Management. ( 28076011 )
2017

Variations for Pulmonary Tuberculosis

Expression for Pulmonary Tuberculosis

LifeMap Discovery
Genes differentially expressed in tissues of Pulmonary Tuberculosis patients vs. healthy controls: 35 (show all 44)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 GBP6 guanylate binding protein family, member 6 Blood + 4.38 0.000
2 ANKRD22 ankyrin repeat domain 22 Blood + 4.04 0.000
3 PDCD1LG2 programmed cell death 1 ligand 2 Blood + 4.03 0.000
4 RLTPR RGD motif, leucine rich repeats, tropomodulin domain and proline-rich containing Blood - 3.89 0.000
5 CD274 CD274 molecule Blood + 3.87 0.000
6 CD248 CD248 molecule, endosialin Blood - 3.84 0.000
7 SPIB Spi-B transcription factor (Spi-1/PU.1 related) Blood - 3.81 0.000
8 LRRN3 leucine rich repeat neuronal 3 Blood - 3.61 0.000
9 LINC00668 long intergenic non-protein coding RNA 668 Blood + 3.60 0.000
10 C1QC complement component 1, q subcomponent, C chain Blood + 3.56 0.000
11 CR1 complement component (3b/4b) receptor 1 (Knops blood group) Blood + 3.54 0.000
12 AEBP1 AE binding protein 1 Blood - 3.53 0.000
13 KREMEN1 kringle containing transmembrane protein 1 Blood + 3.49 0.000
14 CACNA1E calcium channel, voltage-dependent, R type, alpha 1E subunit Blood + 3.46 0.000
15 LGALSL lectin, galactoside-binding-like Blood - 3.43 0.000
16 BATF2 basic leucine zipper transcription factor, ATF-like 2 Blood + 3.42 0.000
17 PLEKHB1 pleckstrin homology domain containing, family B (evectins) member 1 Blood - 3.40 0.000
18 CD22 CD22 molecule Blood - 3.38 0.000
19 BACH1 BTB and CNC homology 1, basic leucine zipper transcription factor 1 Blood + 3.38 0.000
20 NAIP NLR family, apoptosis inhibitory protein Blood + 3.34 0.000
21 EPHB6 EPH receptor B6 Blood - 3.30 0.000
22 DICER1 dicer 1, ribonuclease type III Blood + 3.26 0.000
23 MVD mevalonate (diphospho) decarboxylase Blood - 3.26 0.000
24 FBLN2 fibulin 2 Blood - 3.26 0.000
25 FBXL16 F-box and leucine-rich repeat protein 16 Blood - 3.23 0.000
26 CR2 complement component (3d/Epstein Barr virus) receptor 2 Blood - 3.21 0.000
27 PRSS33 protease, serine, 33 Blood - 3.21 0.000
28 FGF13 fibroblast growth factor 13 Blood + 3.20 0.000
29 GNPNAT1 glucosamine-phosphate N-acetyltransferase 1 Blood - 3.19 0.000
30 RTKN2 rhotekin 2 Blood - 3.19 0.000
31 EPHA1 EPH receptor A1 Blood - 3.16 0.000
32 APOL6 apolipoprotein L, 6 Blood + 3.16 0.000
33 CRIP2 cysteine-rich protein 2 Blood - 3.15 0.000
34 C1QB complement component 1, q subcomponent, B chain Blood + 3.15 0.000
35 CARD17 caspase recruitment domain family, member 17 Blood + 3.14 0.000
36 SERINC5 serine incorporator 5 Blood - 3.12 0.000
37 HKDC1 hexokinase domain containing 1 Blood - 3.11 0.000
38 NT5E 5'-nucleotidase, ecto (CD73) Blood - 3.10 0.000
39 LINC00342 long intergenic non-protein coding RNA 342 Blood + 3.10 0.000
40 PMEPA1 prostate transmembrane protein, androgen induced 1 Blood - 3.09 0.000
41 FCGBP Fc fragment of IgG binding protein Blood - 3.07 0.000
42 SALL2 spalt-like transcription factor 2 Blood - 3.06 0.000
43 GPA33 glycoprotein A33 (transmembrane) Blood - 3.02 0.000
44 SLC27A5 solute carrier family 27 (fatty acid transporter), member 5 Blood - 3.00 0.000
Search GEO for disease gene expression data for Pulmonary Tuberculosis.

Pathways for Pulmonary Tuberculosis

Pathways related to Pulmonary Tuberculosis according to GeneCards Suite gene sharing:

(show top 50) (show all 59)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.01 HLA-DRB1 HP IFNG IFNGR1 IL10 IL12RB1
2
Show member pathways
13.56 IFNG IFNGR1 IL10 IL12RB1 IL18 IL2
3
Show member pathways
13.45 IL10 IL12RB1 IL18 IL2 IL4 TLR2
4
Show member pathways
13.42 HLA-DRB1 IFNG IFNGR1 IL10 IL12RB1 IL18
5
Show member pathways
13.27 HLA-DRB1 IFNG IFNGR1 IL2 IL4 TLR2
6
Show member pathways
12.9 HLA-DRB1 IFNG IL10 IL2 IL4 TNF
7 12.85 IFNG IFNGR1 IL12RB1 IL2 IL4
8
Show member pathways
12.78 HLA-DRB1 IFNG IFNGR1 IL18 IL2 IL4
9
Show member pathways
12.66 IFNG IL10 IL12RB1 IL18 IL2 TNF
10 12.63 IFNG IL10 IL2 IL4 TLR2 TLR9
11
Show member pathways
12.61 HLA-DRB1 IFNG IFNGR1 IL10 IL12RB1 IL18
12
Show member pathways
12.59 IFNG IFNGR1 IL10 IL2 TLR2 TLR9
13
Show member pathways
12.57 IFNG IFNGR1 IL2 IL4 TNF
14
Show member pathways
12.49 IFNG IL10 IL2 IL4 TNF
15
Show member pathways
12.44 IFNG IFNGR1 IL10 IL12RB1 IL2 IL4
16
Show member pathways
12.39 HLA-DRB1 IFNG IFNGR1 IL10 IL12RB1 IL18
17
Show member pathways
12.35 IFNG IL2 IL4 TNF
18
Show member pathways
12.35 IFNG IL4 TLR2 TNF
19
Show member pathways
12.29 HLA-DRB1 IFNG IFNGR1 IL10 IL4 TLR2
20 12.27 IFNG IFNGR1 TLR2 TLR9 TNF
21
Show member pathways
12.24 IFNG IFNGR1 IL4 TLR2 TLR9 TNF
22
Show member pathways
12.21 IFNG IL10 IL18 IL2 IL4 TNF
23 12.09 IFNG IL10 IL2 IL4 TNF
24 12.07 IFNG IL2 IL4 TNF
25 12.04 IL10 IL18 IL4 TNF
26
Show member pathways
12.02 HLA-DRB1 IFNG IL12RB1 IL18 IL2 IL4
27
Show member pathways
11.97 IFNG IL12RB1 IL4 TLR2 TLR9
28 11.96 HLA-DRB1 IFNG IL18 TLR2 TNF
29 11.95 IFNG IL10 TLR2 TNF
30 11.95 IFNG IFNGR1 IL10 IL12RB1 IL2
31 11.86 HLA-DRB1 IFNG IFNGR1 IL10 IL18 TLR2
32
Show member pathways
11.85 IFNG IL2 IL4 TNF
33 11.83 IFNG IFNGR1 IL18
34 11.83 IFNG IL10 IL2 TLR9 TNF
35 11.81 IFNG IL2 IL4
36 11.77 IFNG IL10 IL12RB1 IL18 IL2 IL4
37 11.75 IL10 IL4 TLR2 TLR9 TNF
38
Show member pathways
11.69 IFNG IL2 TNF
39
Show member pathways
11.67 IFNG IL2 TNF
40 11.63 HLA-DRB1 IL10 MBL2
41 11.63 IL10 IL18 IL4 TNF
42 11.62 IL18 TLR2 TNF
43 11.62 IFNG IL18 TLR2 TNF
44 11.6 IFNG IL10 IL2 IL4
45 11.59 IFNG IL2 TNF
46
Show member pathways
11.58 IFNG IFNGR1 TNF
47 11.56 IFNG IL2 TNF
48 11.54 IFNG IL10 IL18 TLR2 TLR9 TNF
49 11.52 IFNG TNF VDR
50
Show member pathways
11.48 IFNG IL10 IL2 TNF

GO Terms for Pulmonary Tuberculosis

Cellular components related to Pulmonary Tuberculosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 HP IFNG IL10 IL18 IL2 IL4
2 external side of plasma membrane GO:0009897 9.46 ADA HLA-DRB1 P2RX7 TNF
3 extracellular space GO:0005615 9.36 ADA HP IFNG IL10 IL18 IL2

Biological processes related to Pulmonary Tuberculosis according to GeneCards Suite gene sharing:

(show top 50) (show all 54)
# Name GO ID Score Top Affiliating Genes
1 response to lipopolysaccharide GO:0032496 9.98 IL10 P2RX7 SLC11A1 TLR2
2 positive regulation of protein phosphorylation GO:0001934 9.96 IFNG IL2 P2RX7 TNF
3 inflammatory response GO:0006954 9.95 IL10 IL18 P2RX7 SLC11A1 TLR2 TLR9
4 cellular response to organic cyclic compound GO:0071407 9.87 IL18 P2RX7 TNF
5 interferon-gamma-mediated signaling pathway GO:0060333 9.87 HLA-DRB1 IFNG IFNGR1
6 defense response to Gram-positive bacterium GO:0050830 9.87 MBL2 P2RX7 TLR2 TNF
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.86 IFNG IL18 IL2
8 interleukin-12-mediated signaling pathway GO:0035722 9.85 IFNG IL10 IL12RB1
9 positive regulation of inflammatory response GO:0050729 9.84 IL18 IL2 TLR2 TLR9
10 extrinsic apoptotic signaling pathway GO:0097191 9.83 IFNG P2RX7 TNF
11 lipopolysaccharide-mediated signaling pathway GO:0031663 9.8 IL18 TLR2 TNF
12 defense response to bacterium GO:0042742 9.8 HP IL10 MBL2 SLC11A1 TLR9 TNF
13 positive regulation of phagocytosis GO:0050766 9.79 MBL2 SLC11A1 TNF
14 positive regulation of cytokine secretion GO:0050715 9.79 IL10 P2RX7 TNF
15 positive regulation of interleukin-8 production GO:0032757 9.78 TLR2 TLR9 TNF
16 positive regulation of interleukin-6 production GO:0032755 9.78 P2RX7 TLR2 TLR9 TNF
17 positive regulation of activated T cell proliferation GO:0042104 9.77 IL12RB1 IL18 IL2
18 negative regulation of interleukin-6 production GO:0032715 9.77 IL10 TLR9 TNF
19 positive regulation of gene expression GO:0010628 9.76 IFNG IL18 P2RX7 SLC11A1 TLR2 TLR9
20 positive regulation of interleukin-12 production GO:0032735 9.75 IFNG TLR2 TLR9
21 positive regulation of chemokine production GO:0032722 9.73 TLR2 TLR9 TNF
22 positive regulation of B cell proliferation GO:0030890 9.73 ADA IL2 IL4 TLR9
23 regulation of interferon-gamma-mediated signaling pathway GO:0060334 9.72 IFNG IFNGR1
24 positive regulation of T cell differentiation GO:0045582 9.72 ADA IL2 IL4
25 positive regulation of interleukin-17 production GO:0032740 9.71 IL18 IL2
26 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.71 IL10 TNF
27 I-kappaB phosphorylation GO:0007252 9.71 TLR2 TLR9
28 regulation of cytokine secretion GO:0050707 9.71 TLR2 TLR9
29 positive regulation of T cell mediated cytotoxicity GO:0001916 9.7 IL12RB1 P2RX7
30 T-helper 1 type immune response GO:0042088 9.7 HLA-DRB1 IL18
31 positive regulation of granulocyte macrophage colony-stimulating factor production GO:0032725 9.7 IL18 TLR9
32 negative regulation of growth of symbiont in host GO:0044130 9.7 IL10 MBL2 TNF
33 positive regulation of isotype switching to IgG isotypes GO:0048304 9.69 IL2 IL4
34 positive regulation of T-helper 1 type immune response GO:0002827 9.69 IL12RB1 SLC11A1
35 response to molecule of bacterial origin GO:0002237 9.69 IL10 TLR2 TLR9
36 endothelial cell apoptotic process GO:0072577 9.68 IL10 TNF
37 positive regulation of MHC class II biosynthetic process GO:0045348 9.68 IL10 IL4
38 negative regulation of cytokine secretion involved in immune response GO:0002740 9.67 IL10 TNF
39 positive regulation of tissue remodeling GO:0034105 9.67 IL18 IL2
40 negative regulation of interleukin-8 production GO:0032717 9.66 IL10 TLR9
41 regulation of isotype switching GO:0045191 9.65 IL10 IL4
42 positive regulation of interleukin-18 production GO:0032741 9.65 TLR2 TLR9
43 tumor necrosis factor production GO:0032640 9.64 TLR2 TLR9
44 positive regulation of toll-like receptor signaling pathway GO:0034123 9.64 TLR2 TLR9
45 receptor biosynthetic process GO:0032800 9.63 IL10 TNF
46 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.63 IFNG TNF
47 positive regulation of vitamin D biosynthetic process GO:0060557 9.58 IFNG TNF
48 positive regulation of NF-kappaB import into nucleus GO:0042346 9.56 IL18 TLR2 TLR9 TNF
49 type 2 immune response GO:0042092 9.54 IL10 IL18 IL4
50 positive regulation of interferon-gamma production GO:0032729 9.35 IL12RB1 IL18 IL2 SLC11A1 TNF

Molecular functions related to Pulmonary Tuberculosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.26 IL10 IL2 IL4 INHA
2 cytokine activity GO:0005125 9.17 IFNG IL10 IL18 IL2 IL4 INHA

Sources for Pulmonary Tuberculosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....